Cargando…

Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT

BACKGROUND: Chronic active Epstein-Barr virus infection (CAEBV) is a rare but life-threatening progressive disease. Human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is the best choice as sometimes HLA-matched donor is not accessible. However, graft-ve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Rongmu, Zhang, Xiaomei, Wang, Ya, Man, Qihang, Gu, Wenjing, Tian, Zhengqin, Wang, Jingbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716678/ https://www.ncbi.nlm.nih.gov/pubmed/36461028 http://dx.doi.org/10.1186/s13023-022-02585-2

Ejemplares similares

Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion
por: Qi, Ling, et al.
Publicado: (2021)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Posttransplant de novo DSA and NDSA affect GvHD, OS, and DFS after haplo-HSCT in patients without pre-existing HLA antibodies of hematological malignancies
por: Wang, Lan, et al.
Publicado: (2022)

Oral Cancer in HSCT Pediatric Patients Arising on GVHD: A Comprehensive Review
por: Cantile, Tiziana, et al.
Publicado: (2022)

Pathophysiology of GvHD and Other HSCT-Related Major Complications
por: Ghimire, Sakhila, et al.
Publicado: (2017)

Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias
por: Fierro-Pineda, Juan C., et al.
Publicado: (2023)

Fulminant isolated adenovirus hepatitis 5 months after haplo-identical HSCT for AML
por: Detrait, Marie, et al.
Publicado: (2015)

P1324: EFFICACY AND SAFETY OF DOSE-ADJUSTED ATG COMBINED WITH CD25 ANTIBODY IN THE PREVENTION OF GVHD AFTER HAPLO-HSCT: CLINICAL STUDY DATA FROM A SINGLE CENTER IN CHINA
por: Zhu, Lidan, et al.
Publicado: (2023)

Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Tafazoli, Ali, et al.
Publicado: (2019)

GVHD Prophylaxis 2020
por: Gooptu, Mahasweta, et al.
Publicado: (2021)

Phenotypic and Functional Characterization of NK Cells in αβT-Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia
por: Meazza, Raffaella, et al.
Publicado: (2020)

Tacrolimus initial steady state level in post-transplant cyclophosphamide based GvHD prophylaxis regimens
por: Yao, Janny M., et al.
Publicado: (2022)

Features of Epstein–Barr Virus and Cytomegalovirus Reactivation in Acute Leukemia Patients After Haplo-HCT With Myeloablative ATG-Containing Conditioning Regimen
por: Ru, Yuhua, et al.
Publicado: (2022)

Haplo ever after: haplo PTCy for children
por: Talano, Julie-An, et al.
Publicado: (2023)

Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2021)

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors
por: Wang, Wen-hui, et al.
Publicado: (2023)

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2020)

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease
por: Vezina, Heather E, et al.
Publicado: (2009)

Chronic active Epstein–Barr virus infection manifesting as coronary artery aneurysm and uveitis
por: Xiao, Haijuan, et al.
Publicado: (2020)

Successful Treatment of Relapsed Epstein–Barr Virus-Associated Hemophagocytic Lymphohistiocytosis After Allo-HSCT with PD-1 Blockade: A Case Report
por: Pi, Yubo, et al.
Publicado: (2022)

Risk and promise: an 11-year, single-center retrospective study of severe acute GVHD in pediatric patients undergoing allogeneic HSCT for nonmalignant diseases
por: Zaidman, Irina, et al.
Publicado: (2023)

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
por: Stenger, Elizabeth O., et al.
Publicado: (2023)

Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Human Amniotic Mesenchymal Stem Cells Alleviate aGVHD after allo-HSCT by Regulating Interactions between Gut Microbiota and Intestinal Immunity
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Risk prediction for liver injury in Epstein-Barr virus infection in pediatric respiratory tract infections
por: Mao, Song, et al.
Publicado: (2023)

PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients
por: Hossain, Mohammad S., et al.
Publicado: (2017)

GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
por: Muranushi, Hiroyuki, et al.
Publicado: (2020)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

P1329: POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) VERSUS ANTITHYMOCYTE GLOBULIN (ATG) AS GVHD PROPHYLAXIS FOR MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION.
por: Dachy, F., et al.
Publicado: (2022)

Association between Antiviral Prophylaxis and Cytomegalovirus and Epstein–Barr Virus DNAemia in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Diop, Ndeye Soukeyna, et al.
Publicado: (2021)

Sintilimab treatment for chronic active Epstein–Barr virus infection and Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children
por: Chen, Ruyue, et al.
Publicado: (2023)

Microascus cirrosus SZ 2021: A potentially new genotype of Microascus cirrosus, which can cause fatal pulmonary infection in patients with acute leukemia following haplo‑HSCT
por: Cheng, Jianjun, et al.
Publicado: (2023)

Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma
por: Hau, Pok Man, et al.
Publicado: (2020)

Editorial: Epstein-Barr virus and its contribution to pediatric tumors
por: Chabay, Paola, et al.
Publicado: (2022)

The Epstein-Barr Virus
por: Payne, L. N.
Publicado: (1980)

PD-1 Checkpoint Blockade in Patients for Acute Myeloid Leukemia after HSCT Relapse Resulted in Severe GVHD and sHLH
por: Du, Zhi zhuo, et al.
Publicado: (2022)

Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
por: Yao, Ji‐Jin, et al.
Publicado: (2017)

Clinical Significance of Haplo-Fever and Cytokine Profiling After Graft Infusion in Allogeneic Stem Cell Transplantation From Haplo-Identical Donors
por: Wang, Lining, et al.
Publicado: (2022)

The role of Epstein–Barr virus in epithelial malignancies
por: Tsao, Sai-Wah, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_301m0mum37r66vi65pbcrnv550